Effect of metformin treatment on insulin action in diabetic rats

In vivo and in vitro correlations

Luciano Rossetti, Ralph A Defronzo, Roberto Gherzi, Peter Stein, Gabriella Andraghetti, Giorgio Falzetti, Gerald I. Shulman, Eveline Klein-Robbenhaar, Renzo Cordera

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

The mechanism (both at the whole body and cellular level) by which metformin improves insulin sensitivity has yet to be defined. In the present study, we examined in vivo insulin-mediated whole-body glucose disposal, glycogen synthesis, hepatic glucose production, and insulin secretion, as well as in vitro muscle insulin receptor tyrosine kinase activity in eight control, eight neonatal streptozotocin diabetic rats, and eight diabetic rats before and after treatment with metformin. Ten weeks after birth diabetic rats had higher fasting (132 + 5 v 101 + 2 mg/dL) and postmeal (231 + 10 v 133 + 3) plasma glucose levels compared with controls (P < .001). Metformin treatment was followed by a significant decrease in the growth rate and normalized glucose tolerance without enhancing the deficient insulin response. Insulin-mediated glucose uptake in diabetic versus control rats was reduced (P < .01) during the high-dose (15.4 + 0.6 v 18.3 + 1.0 mg/kg · min) insulin clamp study and was increased to values greater (P < .05) than controls following metformin treatment. Muscle glycogen synthetic rate in vivo, measured by incorporation of 3H-3-glucose radioactivity, was diminished by 25% (P < .01) in diabetic rats, restored to normal values with metformin, and correlated closely (r = .82, P < .002) with total-body glucose uptake during the insulin clamp in all three groups. Insulin receptor tyrosine kinase activity, measured in partially purified insulin receptors, was reduced in diabetic rats and increased to supernormal levels after metformin. The decrease in muscle tyrosine kinase activity in diabetic versus control animals was entirely accounted for by a reduction in maximal velocity (Vmax) (32 v 45 pmol/mg · min, P < .01) and increased to supernormal levels following metformin (91 pmol/mg · min, P < .001) without any change in affinity (Km). Muscle tyrosine kinase activity was closely correlated with both the muscle glycogen synthetic rate (r = .82, P < .002) and total-body insulin-mediated glucose disposal (r = .64, P < .01) in vivo. The close correlation between in vivo insulin action, muscle glycogen synthesis, and muscle insulin receptor tyrosine kinase activity is consistent with an important role of the enzyme in the insulin resistance of diabetes and its improvement following metformin treatment.

Original languageEnglish (US)
Pages (from-to)425-435
Number of pages11
JournalMetabolism
Volume39
Issue number4
DOIs
StatePublished - 1990

Fingerprint

Metformin
Insulin
Glucose
Muscles
Glycogen
Protein-Tyrosine Kinases
Insulin Resistance
Liver Glycogen
In Vitro Techniques
Insulin Receptor
Streptozocin
Radioactivity
Fasting
Reference Values
Parturition
Enzymes
Growth

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Effect of metformin treatment on insulin action in diabetic rats : In vivo and in vitro correlations. / Rossetti, Luciano; Defronzo, Ralph A; Gherzi, Roberto; Stein, Peter; Andraghetti, Gabriella; Falzetti, Giorgio; Shulman, Gerald I.; Klein-Robbenhaar, Eveline; Cordera, Renzo.

In: Metabolism, Vol. 39, No. 4, 1990, p. 425-435.

Research output: Contribution to journalArticle

Rossetti, L, Defronzo, RA, Gherzi, R, Stein, P, Andraghetti, G, Falzetti, G, Shulman, GI, Klein-Robbenhaar, E & Cordera, R 1990, 'Effect of metformin treatment on insulin action in diabetic rats: In vivo and in vitro correlations', Metabolism, vol. 39, no. 4, pp. 425-435. https://doi.org/10.1016/0026-0495(90)90259-F
Rossetti, Luciano ; Defronzo, Ralph A ; Gherzi, Roberto ; Stein, Peter ; Andraghetti, Gabriella ; Falzetti, Giorgio ; Shulman, Gerald I. ; Klein-Robbenhaar, Eveline ; Cordera, Renzo. / Effect of metformin treatment on insulin action in diabetic rats : In vivo and in vitro correlations. In: Metabolism. 1990 ; Vol. 39, No. 4. pp. 425-435.
@article{2826ee375d054f0a82083e35085b5da3,
title = "Effect of metformin treatment on insulin action in diabetic rats: In vivo and in vitro correlations",
abstract = "The mechanism (both at the whole body and cellular level) by which metformin improves insulin sensitivity has yet to be defined. In the present study, we examined in vivo insulin-mediated whole-body glucose disposal, glycogen synthesis, hepatic glucose production, and insulin secretion, as well as in vitro muscle insulin receptor tyrosine kinase activity in eight control, eight neonatal streptozotocin diabetic rats, and eight diabetic rats before and after treatment with metformin. Ten weeks after birth diabetic rats had higher fasting (132 + 5 v 101 + 2 mg/dL) and postmeal (231 + 10 v 133 + 3) plasma glucose levels compared with controls (P < .001). Metformin treatment was followed by a significant decrease in the growth rate and normalized glucose tolerance without enhancing the deficient insulin response. Insulin-mediated glucose uptake in diabetic versus control rats was reduced (P < .01) during the high-dose (15.4 + 0.6 v 18.3 + 1.0 mg/kg · min) insulin clamp study and was increased to values greater (P < .05) than controls following metformin treatment. Muscle glycogen synthetic rate in vivo, measured by incorporation of 3H-3-glucose radioactivity, was diminished by 25{\%} (P < .01) in diabetic rats, restored to normal values with metformin, and correlated closely (r = .82, P < .002) with total-body glucose uptake during the insulin clamp in all three groups. Insulin receptor tyrosine kinase activity, measured in partially purified insulin receptors, was reduced in diabetic rats and increased to supernormal levels after metformin. The decrease in muscle tyrosine kinase activity in diabetic versus control animals was entirely accounted for by a reduction in maximal velocity (Vmax) (32 v 45 pmol/mg · min, P < .01) and increased to supernormal levels following metformin (91 pmol/mg · min, P < .001) without any change in affinity (Km). Muscle tyrosine kinase activity was closely correlated with both the muscle glycogen synthetic rate (r = .82, P < .002) and total-body insulin-mediated glucose disposal (r = .64, P < .01) in vivo. The close correlation between in vivo insulin action, muscle glycogen synthesis, and muscle insulin receptor tyrosine kinase activity is consistent with an important role of the enzyme in the insulin resistance of diabetes and its improvement following metformin treatment.",
author = "Luciano Rossetti and Defronzo, {Ralph A} and Roberto Gherzi and Peter Stein and Gabriella Andraghetti and Giorgio Falzetti and Shulman, {Gerald I.} and Eveline Klein-Robbenhaar and Renzo Cordera",
year = "1990",
doi = "10.1016/0026-0495(90)90259-F",
language = "English (US)",
volume = "39",
pages = "425--435",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Effect of metformin treatment on insulin action in diabetic rats

T2 - In vivo and in vitro correlations

AU - Rossetti, Luciano

AU - Defronzo, Ralph A

AU - Gherzi, Roberto

AU - Stein, Peter

AU - Andraghetti, Gabriella

AU - Falzetti, Giorgio

AU - Shulman, Gerald I.

AU - Klein-Robbenhaar, Eveline

AU - Cordera, Renzo

PY - 1990

Y1 - 1990

N2 - The mechanism (both at the whole body and cellular level) by which metformin improves insulin sensitivity has yet to be defined. In the present study, we examined in vivo insulin-mediated whole-body glucose disposal, glycogen synthesis, hepatic glucose production, and insulin secretion, as well as in vitro muscle insulin receptor tyrosine kinase activity in eight control, eight neonatal streptozotocin diabetic rats, and eight diabetic rats before and after treatment with metformin. Ten weeks after birth diabetic rats had higher fasting (132 + 5 v 101 + 2 mg/dL) and postmeal (231 + 10 v 133 + 3) plasma glucose levels compared with controls (P < .001). Metformin treatment was followed by a significant decrease in the growth rate and normalized glucose tolerance without enhancing the deficient insulin response. Insulin-mediated glucose uptake in diabetic versus control rats was reduced (P < .01) during the high-dose (15.4 + 0.6 v 18.3 + 1.0 mg/kg · min) insulin clamp study and was increased to values greater (P < .05) than controls following metformin treatment. Muscle glycogen synthetic rate in vivo, measured by incorporation of 3H-3-glucose radioactivity, was diminished by 25% (P < .01) in diabetic rats, restored to normal values with metformin, and correlated closely (r = .82, P < .002) with total-body glucose uptake during the insulin clamp in all three groups. Insulin receptor tyrosine kinase activity, measured in partially purified insulin receptors, was reduced in diabetic rats and increased to supernormal levels after metformin. The decrease in muscle tyrosine kinase activity in diabetic versus control animals was entirely accounted for by a reduction in maximal velocity (Vmax) (32 v 45 pmol/mg · min, P < .01) and increased to supernormal levels following metformin (91 pmol/mg · min, P < .001) without any change in affinity (Km). Muscle tyrosine kinase activity was closely correlated with both the muscle glycogen synthetic rate (r = .82, P < .002) and total-body insulin-mediated glucose disposal (r = .64, P < .01) in vivo. The close correlation between in vivo insulin action, muscle glycogen synthesis, and muscle insulin receptor tyrosine kinase activity is consistent with an important role of the enzyme in the insulin resistance of diabetes and its improvement following metformin treatment.

AB - The mechanism (both at the whole body and cellular level) by which metformin improves insulin sensitivity has yet to be defined. In the present study, we examined in vivo insulin-mediated whole-body glucose disposal, glycogen synthesis, hepatic glucose production, and insulin secretion, as well as in vitro muscle insulin receptor tyrosine kinase activity in eight control, eight neonatal streptozotocin diabetic rats, and eight diabetic rats before and after treatment with metformin. Ten weeks after birth diabetic rats had higher fasting (132 + 5 v 101 + 2 mg/dL) and postmeal (231 + 10 v 133 + 3) plasma glucose levels compared with controls (P < .001). Metformin treatment was followed by a significant decrease in the growth rate and normalized glucose tolerance without enhancing the deficient insulin response. Insulin-mediated glucose uptake in diabetic versus control rats was reduced (P < .01) during the high-dose (15.4 + 0.6 v 18.3 + 1.0 mg/kg · min) insulin clamp study and was increased to values greater (P < .05) than controls following metformin treatment. Muscle glycogen synthetic rate in vivo, measured by incorporation of 3H-3-glucose radioactivity, was diminished by 25% (P < .01) in diabetic rats, restored to normal values with metformin, and correlated closely (r = .82, P < .002) with total-body glucose uptake during the insulin clamp in all three groups. Insulin receptor tyrosine kinase activity, measured in partially purified insulin receptors, was reduced in diabetic rats and increased to supernormal levels after metformin. The decrease in muscle tyrosine kinase activity in diabetic versus control animals was entirely accounted for by a reduction in maximal velocity (Vmax) (32 v 45 pmol/mg · min, P < .01) and increased to supernormal levels following metformin (91 pmol/mg · min, P < .001) without any change in affinity (Km). Muscle tyrosine kinase activity was closely correlated with both the muscle glycogen synthetic rate (r = .82, P < .002) and total-body insulin-mediated glucose disposal (r = .64, P < .01) in vivo. The close correlation between in vivo insulin action, muscle glycogen synthesis, and muscle insulin receptor tyrosine kinase activity is consistent with an important role of the enzyme in the insulin resistance of diabetes and its improvement following metformin treatment.

UR - http://www.scopus.com/inward/record.url?scp=0025265036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025265036&partnerID=8YFLogxK

U2 - 10.1016/0026-0495(90)90259-F

DO - 10.1016/0026-0495(90)90259-F

M3 - Article

VL - 39

SP - 425

EP - 435

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 4

ER -